

EUPATI 2013 CONFERENCE

EUPATI: A VISION FOR 2020

19 April, Rome, Italy

INTRODUCTION

The EUPATI consortium is delighted to announce its first EUPATI conference entitled “EUPATI: A Vision for 2020”.

We are looking to the future: 2020 and three years beyond the end of the project, to how tools and knowledge provided through EUPATI could make a difference to patients, advocates, patient organisations and the public.

We want this conference to focus on ‘real world’ healthcare hot topics; which you as conference delegates could relate to.

The conference program has been structured around three key topics: patient involvement in medicines research and development; patients’ voice in access to new medicines; increasing the public awareness of benefits and risks of new treatment development.

Short presentations are designed to inspire a collective vision. Using actual examples we will bring to life existing best practices, discuss future patient involvement and empowerment within medicines development and demonstrate how the Patients’ Academy would add value and bring great benefit.

Together, through the EUPATI lens the conference sets out to explore:

- What would patient involvement in medicines development look like in 2020?
- How will various debates on access to medicines be strengthened by 2020?
- 2020 what increase will we predict in public knowledge about development of new treatments?

We want each conference delegate to participate in shaping and building this vision. Throughout the conference you will have many opportunities to voice your opinions and share your thoughts. Open and active dialogue is strongly encouraged.

At the end of the day we hope each conference delegate will:

- understand the value of courses, materials and information currently being developed by EUPATI
- see how these different resources can be applied to shape the future of medicines development
- and have influenced and informed the EUPATI project.



PROGRAMME COMMITTEE

Silvano Berioli	European Forum for Good Clinical Practice (EFGCP), Belgium
Virginie Delwart	Janssen, Belgium
Matthias Gottwald	Bayer Pharma, Germany
Ingrid Klingmann	European Forum for Good Clinical Practice (EFGCP), Belgium
Liuska Sanna	European Patients' Forum (EPF), Belgium
Soren Skovlund	Novo Nordisk, Denmark
Kim Wever	European Genetic alliance Network (EGAN)/Dutch Genetic Alliance (VSOP), The Netherlands
Kay Warner	GlaxoSmithKline, UK

CONTACT EUPATI

For further information about

The Project: please visit www.patientsacademy.eu or contact the EUPATI secretariat
Tel: +49 89 660 869 68 – E-mail: info@patientsacademy.eu

Participation in the Conference and in the EUPATI Network: The EFGCP Secretariat
Tel: +32 2 732 87 83 – E-mail: eupati@efgcp.eu



The EUPATI project receives support from the European Union (IMI JU) and EFPIA companies

AGENDA

FRIDAY, 19 APRIL 2013

08:30 Registration & Welcome Coffee
09:00 Welcome and Introduction

SESSION 1:

Patient involvement in medicines R&D Process in 2020

How to progress the involvement of patients in the process of medicines development has long been debated. The ultimate goal of EUPATI is to provide dedicated training, information and material to equip and empower more patients to become active partners with academia, industry, regulatory agencies, HTA bodies and ethics committees. This session will set the scene for this step change in approach by sharing examples of current best practice and encourage an exchange of views on how EUPATI can be a catalyst for efficient patient involvement in new treatment development processes across Europe.

09:15 Vision – here we are, where we want to be in 2020
09:35 Best practices
10:05 Bring to life with EUPATI examples
10:20 Open discussion on how to achieve the vision
11:10 **Coffee Break**

SESSION 2:

Building Knowledge & Competences for Patients' Involvement in Medicines R&D

Educating and training patients objectively, efficiently and adapted to their needs in the complex area of medicines research and development requires to take new avenues. Different innovative approaches how to teach a lay audience need to be considered. EUPATI chose the strategic approach of training knowledgeable patient representatives as experts, as well as providing suitable educational material and toolkits for own use with their constituency and local partners. This session will explore best practice examples on patient education pursued by other stakeholders, and discuss which lessons can be learned for EUPATI to facilitate effective and meaningful involvement of patients in R&D.

11:30 Vision – here we are, where we want to be in 2020
11:50 Best practices
12:20 Bring to life with EUPATI examples
12:35 Open discussion on how to achieve the vision
13:30–14:30 **Lunch**



SESSION 3:

Public awareness about new medicines development in 2020

Pharmaceutical medicines development is a highly regulated, costly, long and complex process that is largely unknown to the lay public. Benefits and risks of existing and new treatment alternatives are difficult to understand for the general public. In an era of growing demand and emphasis on both quality and sustainability of healthcare, it is critical to address this major gap in public perception and knowledge.

This session will explore how EUPATI can contribute to overcome current barriers through a coordinated approach of all stakeholders involved in this process and to develop reliable and most up-to-date information and opportunities for involvement of the lay patients and citizens.

- | | |
|---------------|---|
| 14:30 | Vision – here we are, where we want to be in 2020 |
| 14:50 | Best practices |
| 15:20 | Bring to life with EUPATI examples |
| 15:35 | Open discussion on how to achieve the vision |
| 16:30: | Closing discussion: achieving goals |
| 17:00: | Networking Event |